Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...
   
 
                                                                                                
      
 

Resident Seminar - December 15, 2022


 
 
                                                                  

LINK TO   EVALUATION >> (opened after session)

                                               PARKING REQUEST FORM  »                                                     MAP &     DIRECTIONS »
 
 
 
 
RESIDENT SEMINAR SCHEDULE
 
Thursday, December 15, 2022
St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis
         Academic Research Building (ARB) and Virtually
 
 
 
ARB 304
ARB 305
ARB 354
ARB 355
Link to Teams Meeting
Links to Handouts
Check Back Later
Check Back Later
Check Back Later
Check Back Later
SESSION 1
1:00 – 1:45
Caity Blankenship, PharmD
IDH and FLT3 Inhibitor Combinations in Elderly Patients with Newly Diagnosed AML
Alison Rydell, PharmD
Optimizing Treatment for Gram Negative Bacteremia
Lauren Dickman, PharmD
DAPT Management in Bleeding Events: To Continue or Not to Continue?
Miranda Norvell, PharmD
Novel Approaches for the Management of Nonalcoholic Steatohepatitis
1:45 – 1:55 pm
Travel Time to accommodate movement between rooms
SESSION 2
1:55 – 2:40
Katelyn Kennedy, PharmD
Trilaciclib in Chemotherapy-Induced Myelosuppression
Jesus Escamilla, PharmD
Updates on Inhaled Antibiotics for Ventilator-Associated Bacterial Pneumonia
Caitlyn Patton, PharmD
Tenecteplase for the Treatment of Pulmonary Embolism
Farah Alhalabi, PharmD
The role of SGLT2 inhibitors in the treatment   
of heart failure
2:40 – 2:50 pm
Travel Time to accommodate movement between rooms
SESSION 3
2:50 – 3:35
Morgan Blair, PharmD
Emerging Pharmacologic Therapies for Treatment Resistant Depression
Jessica Hall, PharmD
DOACs in LVT: To Be or Not To Be
Lauren Busch, PharmD
Impede the Bleed: Tranexamic Acid for Surgical and Traumatic Bleeds
 
Madison Schmidt, PharmD
The Role of Dual Incretin Agonists in
the Management of Type 2 Diabetes
 
Please join us for the third and final Resident Seminar session of the 2022-2023 academic year. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series focuses on current therapeutic topics in the practice of pharmacy. All sessions will be held in classrooms in the Academic & Research Building (ARB) on the third floor (see classroom numbers above), as well as virtually (see Teams links above).
 
Participants may earn a maximum possible 0.75 contact hour of CPE credit per session. The maximum possible credit that can be earned for this Resident Seminar is 2.25 contact hours. Participants must complete an evaluation (see link above) to receive credit.

Click here for a printable copy of the schedule


REGISTRATION: To register for the LIVE Resident Seminar presentations, click here>>>. There is no need to register for the virtual presentations. Please use the links within the table above to connect to the VIRTUAL presentations. Special note, this event has multiple concurrent sessions.
 
Due to a limited number of live available classroom spaces, a maximum of 30 people are allowed per classroom. Virtual attendance is limitless.

Registration is free but is required in advance for the LIVE presentations. Due to limited space, only those participants who register for the LIVE session before 5:00 PM on Friday, December 9, 2022 will be able to request parking access on campus.

PARKING: To request parking, please first register for your desired LIVE sessions. Then, complete the Parking Request Form using the link above, or complete your parking request by clicking here>>>. If you do not request parking on our campus, or if you do not submit your request by the deadline, you will be re-directed upon arrival.

HANDOUTS: Participants attending the LIVE (on-campus) sessions will be provided paper copies of handouts within the classrooms. Virtual attendees can access the handouts in the table above. Copies of PowerPoint slides are not provided.

ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.

CPE CREDIT: Immediately following Resident Seminar, participants should complete an evaluation for EACH presentation attended (3 maximum) by clicking here>>>. The evaluation link will open immediately following Resident Seminar. Participants will have one week after attending the session to complete the evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live and virtual presentations. Only ONE session may be claimed for each of the three blocks. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
 
It is recommended that participants log on and review the information under "My Account" prior to completing evaluations. The NABP ePID and date of birth fields must be accurate for credit reporting to occur. Participants are encouraged to check their NABP eProfiles for receipt of credit within two weeks of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact ce@uhsp.edu soon as possible. To best comply with ACPE's CE credit reporting policy, the University of Health Sciences and Pharmacy in St. Louis is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
 
After one week, evaluations will close and CPE credit may no longer be claimed. If the deadline is missed or if a CE credit correction must be issued, an additional fee may be incurred for late submission - please see our policy, located on the FAQ page for details. Evaluations close Tuesday, January 3, 2023 at 8:00 AM (CST).

SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify the CE Administrator via email at ce@uhsp.edu in advance so that she may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
 
 
 
 Learn more! Click the + symbol below to expand.

Date: Dec 15, 2022 01:00 AM - 03:35 AM

Fee

$0.00

CE Hours

9.00

Activity Type

  • Knowledge

 

 

 

 

This presentation will begin by describing the importance and prevalence of FLT3 and IDH mutations in the newly diagnosed elderly AML patients that are not candidates for intensive chemotherapy. Then will discuss the current standard of care options for this patient population. Furthermore, we will discuss the specific inhibitors for both IDH and FLT3 and the literature surrounding those medications. Additionally, we will evaluate the literature for combination therapy for FLT3 inhibitors. Lastly, we will compare the standard treatment options to what we have learned about the FLT3 and IDH inhibitors.

Objectives

  • Identify the role in therapy of IDH1, IDH2, and FLT3 inhibitor targeted therapy in newly diagnosed elderly AML patients
  • Evaluate the safety and efficacy of low intensity combination regimens for IDH1, IDH2, and FLT3 mutations in newly diagnosed elderly AML patients

Speaker(s)/Author(s)

Caity Blankenship, PharmD

Activity Number

0033-0000-22-048-L01-P
Date: 12/15/22
Time: 01:00 PM - 01:45 PM

CE Hours

0.75

Location

ARB 304 and Virtually
 

 

Gram-negative bacteremia is a common infection treated in the acute setting.  Previously, these infections were treated with antibiotics for 14 days or more.  There is growing evidence that shorter antibiotic durations may be adequate to treat Gram-negative bacteremia.  There is a lack of guideline recommendations for appropriate duration of antibiotic treatment, as well as for transition from IV therapy to oral therapy.  While fluoroquinolones have the most evidence of the oral therapies for Gram-negative bacteremia, data regarding oral beta-lactams will be presented to discuss their possible role for this infection. This presentation will seek to review primary literature to discuss if shorter antibiotic courses are effective for Gram-negative bacteremia.  Additionally, oral antibiotic therapy options will be reviewed and the optimal timing for the IV to oral transition will be presented.

Objectives

  • Identify the most common causative organisms of Gram-negative bacteremia and current guideline recommendations
  • Describe appropriate oral therapies for Gram-negative bacteremia
  • Evaluate when it may be appropriate to transition from IV to oral therapies

Speaker(s)/Author(s)

Alison Rydell, PharmD

Activity Number

0033-0000-22-046-L01-P
Date: 12/15/22
Time: 01:00 PM - 01:45 PM

CE Hours

0.75

Location

ARB 305 and Virtually
 

 

This presentation will review recent data to help guide management of DAPT in bleeding events. This presentation will review purpose of DAPT and mechanisms of action related to DAPT. Detail of why bleeding is of such high prevalence in DAPT will be reviewed. Current state of guidance will be reviewed. 3 studies will be reviewed investigating duration of therapy, monotherapy, and the use of PPI with DAPT for patients with recent GI bleed on DAPT. The presentation will conclude with recommendations and time for questions.

Objectives

  • Describe the role and purpose for the use of DAPT
  • Identify patients who are candidates for shortened durations of DAPT
  • Discuss the reasoning and selection of monotherapy in select patients previously on DAPT
  • Identify patients on DAPT who are candidates for the addition of PPI therapy

Speaker(s)/Author(s)

Lauren Dickman, PharmD

Activity Number

0033-0000-22-042-L01-P
Date: 12/15/22
Time: 01:00 PM - 01:45 PM

CE Hours

0.75

Location

ARB 354 and Virtually
 

 

There are currently no approved treatment options for nonalcoholic steatohepatitis (NASH). Guidelines recommend considering vitamin E and/or pioglitazone, but also state no firm recommendations can be made surrounding the use of either agent. Many studies have recently been published specifically looking at antidiabetic agents, including DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. These studies have shown promising results for the use of some of these agents. This seminar presentation will focus on reviewing the pathophysiology of NASH and the recent literature available for the management of NASH. The goal of this presentation is for audience members to understand the use of antidiabetic agents for the management of NASH and be able to select appropriate pharmacologic treatment options for patients with NASH.

Objectives

  • Identify the risk factors associated with nonalcoholic steatohepatitis
  • Describe the mechanism of novel antidiabetic agents in relation to the pathophysiology of nonalcoholic steatohepatitis
  • Select appropriate pharmacologic treatment options for patients with nonalcoholic steatohepatitis

Speaker(s)/Author(s)

Miranda Norvell, PharmD

Activity Number

0033-0000-22-045-L01-P
Date: 12/15/22
Time: 01:00 PM - 01:45 PM

CE Hours

0.75

Location

ARB 355 and Virtually
 

 

Trilaciclib is a novel, potent, selective, reversible cyclin dependent kinase 4 and 6 (CDK4/6) inhibitor that sustains G1 cell cycle arrest of hematopoietic stem cells and progenitor cells (HSPC). Trilaciclib was approved by the Federal Food and Drug Administration (FDA) in 2021 for chemotherapy-induced myelosuppression (CIM) associated with the treatment of small-cell lung cancer. The mechanism of action of trilaciclib will protect HSPC from chemotherapy's toxic effects. While current literature potentially suggests the beneficial effects of trilaciclib, there are still questions that are worth addressing. It is important to ask if trilaciclib could be used in other cancer types, as well as, if trilaciclib poses advantageous to other CIM therapies. The goal of this presentation is to delve into the data that led to FDA approval and address if trilaciclib should be utilized. Studies presented will include the current data on efficacy, safety, cost analysis, and ongoing clinical trials.

Objectives

  • Describe the mechanism of action by which trilaciclib prevents CIM in patients with small cell lung cancer
  • Describe the conclusions of the three hallmark studies leading to the Food and Drug Administration's approval of Trilaciclib
  • Identify the patient characteristics that would constitute trilaciclib as a favorable CIM treatment option

Speaker(s)/Author(s)

Katelyn Kennedy, PharmD

Activity Number

0033-0000-22-052-L01-P
Date: 12/15/22
Time: 01:55 PM - 02:40 PM

CE Hours

0.75

Location

ARB 304 and Virtually
 

 

This CE will evaluate literature published after the most recent IDSA and European guidelines for the management of ventilator-associated Gram-negative bacterial pneumonia to determine the current role of inhaled antibiotics in this disease state. The presentation will review current guideline recommendations, limitations associated with the current standard of care, the theoretical benefits of utilizing inhaled aminoglycosides and colistin, and then evaluate literature that assesses patient outcomes in those who receive inhaled antibiotics.

Objectives

  • Discuss the current role of inhaled antibiotics in ventilator-associated pneumonia (VAP)
  • Explain the potential benefit of inhaled aminoglycosides and colistin for the treatment of VAP
  • Summarize the different clinical and microbiological outcomes presented in literature associated with inhaled aminoglycosides and colistin for the treatment of VAP to determine their role in therapy

Speaker(s)/Author(s)

Jesus Escamilla, PharmD

Activity Number

0033-0000-22-043-L01-P
Date: 12/15/22
Time: 01:55 PM - 02:40 PM

CE Hours

0.75

Location

ARB 305 and Virtually
 

 

A pulmonary embolism (PE) is a medical emergency and guideline-recommended therapy is treatment with a systemic thrombolytic in the setting of hemodynamic compromise with evidence of right heart strain. Historically, PE management guidelines have specifically recommended the thrombolytic alteplase but more recent guidelines, including the 2020 American Society of Hematology and the 2021 CHEST guidelines, now include a more generalized recommendation of "thrombolytic therapy." An alternative thrombolytic, tenecteplase, has shown promise as a potential therapy for PE while offering several theoretical advantages to alteplase. This presentation will review and analyze the major literature surrounding the use of thrombolytics in the treatment of PE with focus on the efficacy and safety of tenecteplase.

Objectives

  • Describe the classifications of pulmonary embolism
  • Compare and contrast studies investigating the efficacy and safety of tenecteplase for the treatment of pulmonary embolism
  • Select an appropriate treatment for a patient presenting with pulmonary embolism

Speaker(s)/Author(s)

Caitlyn Patton, PharmD

Activity Number

0033-0000-22-050-L01-P
Date: 12/15/22
Time: 01:55 PM - 02:40 PM

CE Hours

0.75

Location

ARB 354 and Virtually
 

 

This presentation will focus on the updates to the 2022 heart failure guidelines. It outlines the new treatment recommendations for patients with heart failure and compare these recommendations to the previous heart failure guidelines. The presentation will summarize the literature for using SGLT2 inhibitors in patients with heat failure that has led to adding SGLT2 inhibitors as part of guideline mediated therapy for this patient population.

Objectives

  • Classify heart failure based on Left ventricular ejection fraction
  • Compare the treatment recommendations between the 2017 and 2022 AHA/ACC/HFSA guideline
  • Summarize the data supporting the use of SGLT2 inhibitors in patients with heart failure in the 2022 ACC/AHA heart failure guidelines

Speaker(s)/Author(s)

Farah Alhalabi, PharmD

Activity Number

0033-0000-22-044-L01-P
Date: 12/15/22
Time: 01:55 PM - 02:40 PM

CE Hours

0.75

Location

ARB 355 and Virtually
 

 

Major Depressive Disorder (MDD) is a prevalent condition with numerous impacts on society. While guidelines outlining initial therapy for MDD are readily available, guidance for the treatment of depression resistant to traditional antidepressant therapy is lacking. This presentation will review the pathophysiology and treatment recommendations for depression as outlined in the American Psychological Association (APA) guidelines. Furthermore, the presentation will review common agents currently used in the treatment of Treatment Resistant Depression (TRD) and new agents recently approved or under investigation.

Objectives

  • Describe the presentation, incidence and treatment of unipolar depression
  • Define Treatment Resistant Depression (TRD) and its impact on society
  • Discuss existing and emerging pharmacological options for the treatment of TRD

Speaker(s)/Author(s)

Morgan Blair, PharmD

Activity Number

0033-0000-22-049-L01-P
Date: 12/15/22
Time: 02:50 PM - 03:35 PM

CE Hours

0.75

Location

ARB 304 and Virtually
 

 

Anticoagulation is the cornerstone of treating left ventricular thrombi to reduce the risk of stroke and systemic embolism. While direct oral anticoagulants (DOACs) have been approved to reduce the risk of stroke and systemic emboli in patients with nonvalvular atrial fibrillation and for the treatment of other thromboembolisms, there is less available literature to support the use of DOACs in patients with left ventricle thrombi. Furthermore, the guidelines currently recommend the use of warfarin in this setting with little mention of the role of DOACs. This continuing education seminar will provide a review of the available literature comparing the safety and efficacy of warfarin compared to DOACs for this indication.

Objectives

  • Identify risk factors for the development of left ventricular thrombus
  • Summarize guideline recommendations for the treatment of left ventricular thrombus including the agent and duration of treatment
  • Select an appropriate treatment regimen for left ventricular thrombus taking into consideration patient specific factors

Speaker(s)/Author(s)

Jessica Hall, PharmD

Activity Number

0033-0000-22-047-L01-P
Date: 12/15/22
Time: 02:50 PM - 03:35 PM

CE Hours

0.75

Location

ARB 305 and Virtually
 

 

Tranexamic acid (TXA) only has two FDA-approved indications including the treatment of heavy menstrual bleeding and tooth extractions in patient with hemophilia. However, TXA is a commonly used drug with several off-label indications including treatment of postpartum hemorrhage, prevention of bleeding and blood transfusions in surgical patients, as well as prevention of bleeding and blood transfusions in trauma patients. Many clinicians use TXA in these situations, but may not know the data behind these off-label indications and the issues with well-known trials that are often referenced to support the use of TXA. This presentation will address the clinical controversies surrounding TXA and will critique TXA trials in various patient populations, with a focus on trauma and surgical patients. A final recommendation regarding the safety and efficacy of TXA in these patient populations will be made, including what clinical controversies remain unanswered.

Objectives

  • Describe the risks and benefits of tranexamic acid (TXA) use in trauma and surgical patients
  • Explain the clinical controversies and unanswered questions behind the use of TXA

Speaker(s)/Author(s)

Lauren Busch, PharmD

Activity Number

0033-0000-22-051-L01-P
Date: 12/15/22
Time: 02:50 PM - 03:35 PM

CE Hours

0.75

Location

ARB 354 and Virtually
 

 

This presentation will focus on the newly approved dual incretin agonist class for the treatment of type 2 diabetes.  Given its recent approval, there is a lack of guidance on when they should be used in the American Diabetes Association Guidelines. Therefore, this presentation will review dual incretin agonists and provide the necessary information for health care providers to clinically apply its use in the treatment of diabetes. Specifically, pathophysiology, mechanism of action, and place of therapy of dual incretin agonist will be covered. To determine place of therapy as well as efficacy and safety of this medication class, the recent data on dual incretin agonists will be reviewed and analyzed to draw clinical conclusions.

Objectives

  • Describe the incretin effect and identify the incretins involved
  • Explain the mechanism of action of a dual incretin agonist
  • Summarize the primary outcome and safety outcomes of the SURPASS-2 Trial
  • Identify place in therapy of dual incretin agonists for patients with type 2 diabetes

Speaker(s)/Author(s)

Madison Schmidt, PharmD, MBA

Activity Number

0033-0000-22-041-L01-P
Date: 12/15/22
Time: 02:50 PM - 03:35 PM

CE Hours

0.75

Location

ARB 355 and Virtually